At the news
? BEARISHIMPACT 7/10 8-K/A filed Nov 9, 2026 at 16:07 ET
Artiva Biotherapeutics filed an amended 8-K providing cost estimates for its wind-down, which includes discontinuing its lead drug candidate AlloNK (AB-101) and reducing its workforce by approximately 94%. The company estimates $10M-$15M in contract termination costs for clinical trial close-outs and $17M-$20M in workforce reduction costs, with most charges expected in Q4 2026. The company continues to explore strategic alternatives to maximize stockholder value.
- Board approved discontinuation of AlloNK (AB-101) development
- Workforce reduction of approximately 94% of current employee base
- Estimated $10M to $15M in contract termination and clinical trial close-out costs
- Estimated $17M to $20M in workforce reduction costs (severance, benefits, payroll taxes)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access